Prognostic significance of transcription factors FOXA1 and GATA-3 in ductal carcinoma in situ in terms of recurrence and estrogen receptor status

Abstract

Aim: The aim was to analyze the expression of novel biological transcription markers, forkhead-box A1 (FOXA1), GATA binding protein 3 (GATA-3), and established markers such as Ki-67 (MIB-1) and human epidermal growth factor receptor 2 (HER2) in estrogen receptor (ER(+)) and ER(-) ductal carcinoma in situ (DCIS) patients with/without recurrence.

Methods: Two hundred and ninety-one cases of DCIS were retrieved from our pathology database, with complete data available for 219 cases. The follow-up period is from 1988 to 2009. Recurrence is defined in terms of DCIS or invasive carcinoma (IC). No recurrence was seen in 88% (196/219) of cases; 12% (26/219) had a recurrence (IC: 13, DCIS: 13). We are reporting the results of biological marker expression in terms of recurrence and ER status.

Results: Our study demonstrates strong expression of GATA-3 in the ER(+) DCIS in recurrence and nonrecurrence groups similar to previously described in IC. A reduced expression of GATA-3 was observed in ER(-) recurrence and nonrecurrence groups. A strong HER2 protein expression, as well as high proliferation index, was seen in recurrence group (DCIS and IC). FOXA1 expression is reduced across the groups though not statistically significant.

Conclusion: This is the first study to analyze novel transcription markers FOXA1 and GATA-3 in DCIS. Further work needs to be done on a larger cohort of DCIS cases with recurrence to better understand, which variables are best able to predict recurrence and guide therapy decision strategies. Maintenance of FOXA1 and GATA-3 expression in ER(-) DCIS may offer new promising targets for therapy in future.

Keywords

Ductal carcinoma in situ / estrogen receptor / forkhead-box A1 / GATA binding protein 3

References

[1] Ernster VL,Kerlikowske K,Henderson C.Incidence of and treatment for ductal carcinoma in situ of the breast..JAMA1996;275:913-8

[2] Ernster VL,Barlow WE,Weaver DL,Yankaskas BC,Carney PA,Taplin SH,Geller BM.Detection of ductal carcinoma in situ in women undergoing screening mammography..J Natl Cancer Inst2002;94:1546-54

[3] Altintas S,Huizing MT,Asjoe FT,Van Marck E,Praet M,Vermorken JB.Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study..Breast J2009;15:120-32

[4] Allred DC,Mao S,Lee S,Mohsin SK,Tsimelzon A.Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution..Clin Cancer Res2008;14:370-8

[5] Tang P,Schiffhauer L,Bourne P,Quinn A.Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers..Ann Clin Lab Sci2006;36:16-22

[6] Livasy CA,Karaca G,Maia D,Tse CK,Millikan RC.Identification of a basal-like subtype of breast ductal carcinoma in situ..Hum Pathol2007;38:197-204

[7] Tamimi RM,Marotti J,Galaburda L,Deitz AC,Schnitt SJ,Collins LC.Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer..Breast Cancer Res2008;10:404-13 PMCID:PMC2575540

[8] Provenzano E,Giles GG,Venter DJ.Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast..Eur J Cancer2003;39:622-30

[9] Jordan VC,Mirecki DM,Welshons WV.Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast..Crit Rev Clin Lab Sci1988;26:97-152

[10] Badve S,Thorat MA,Nielsen TO,Dunn S,Nakshatri H.FOXA1 expression in breast cancer - correlation with luminal subtype A and survival..Clin Cancer Res2007;13:4415-21

[11] Thorat MA,Morimiya A,Nakshatri H,Badve S.Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis..J Clin Pathol2008;61:327-32

[12] Albergaria A,Sousa B,Carneiro V,Costa S,Lopes N,Lunet N.Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours..Breast Cancer Res2009;11:R40

[13] Habashy HO,Rakha EA,Paish C,Nicholson RI.Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance..Eur J Cancer2008;44:1541-51

[14] Lacroix M.About GATA-3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer..Mol Cell Endocrinol2004;219:1-7

[15] Kourzarides T.Chromatin modifications and their function..Cell2007;128:693-705

[16] Williamson EA,O'Kelly J,Tanosaki S.BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)..Oncogene2006;25:1391-9

[17] Wolf I,Williamson EA,Karlan BY.FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer..Int J Cancer2007;120:1013-22

[18] Ho IC,Marin N,Tsai SF,Leiden JM.Human GATA3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor gene..EMBO J1991;10:1187-92

[19] Hoch RV,Baker RJ.GATA-3 is expressed in association with estrogen receptor in breast cancer..Int J Cancer1999;84:122-8

[20] Kouros-Mehr H,Sternlicht MD.GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland..Cell2006;127:1041-55 PMCID:PMC2646406

[21] Kouros-Mehr H,Bechis SK.GATA-3 and the regulation of the mammary luminal cell fate..Curr Opin Cell Biol2008;20:164-70 PMCID:PMC2397451

[22] Jacquemier J,Monville F,Extra JM,Xerri L,Birnbaum D.Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer..Breast Cancer Res2009;11:R23

[23] Mehra R,Ding L,Sabel MS,Chinnaiyan AM.Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis..Cancer Res2005;65:11259-64

[24] Carroll JS,Brodsky AS,Meyer CA,Eeckhoute J,Hestermann EV,Fox EA,Brown M.Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1..Cell2005;122:33-43

[25] Carroll JS.Estrogen receptor target gene: an evolving concept..Mol Endocrinol2006;20:1707-14

[26] Laganiere J,Lefebvre C,Robert F.From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response..Proc Natl Acad Sci U S A2005;102:11651-6 PMCID:PMC1183449

[27] Nakshatri H.FOXA1 in breast cancer..Expert Rev Mol Med2009;11:e8

[28] Keeple J,Klimberg VS,Siegel E,Korourian S.The receptor expression pattern in ductal carcinoma in situ predicts recurrence..Am J Surg2006;192:68-71